Nanodelivery of arsenic fights lymphoma while preserving fertility

Share this article:

Packaging crystalline arsenic particles in a bubble of fat helps deliver the drug into lymphoma cells without damaging ovarian tissue, follicles, or eggs, recent research has demonstrated.

The drug delivery system, known as a nanobin, consists of the fat bubble, or liposome, densely packed with half a million molecules of arsenic trioxide. Arsenic trioxide is a potent agent for the treatment of hematologic malignancies.

Because the liposome is hundreds of times smaller than the average cell, it can easily slip into tumor-nourishing blood vessels. According to a statement from Northwestern University in Chicago, Illinois, where the nanobin was developed, acid in the cancer cells triggers the release of the liposome's drug cargo so that a highly effective dose of arsenic trioxide is delivered where it is needed.

When Teresa K. Woodruff, chief of fertility preservation at Northwestern University Feinberg School of Medicine, and her husband Thomas O'Halloran, director of the Chemistry and Life Processes Institute at Northwestern, developed and tested the nanobin, they found that the arsenic trioxide had significantly better activity in that form than did the free drug in a mouse model of lymphoma.

The coprincipal investigators and their fellow researchers also developed an in vitro test of ovarian follicle function that predicts in vivo ovarian toxicity of therapeutic agents. They found that the nanotherapeutic arsenic trioxide was not only more active against lymphoma but also less deleterious to ovarian function than was the parent drug.

“The drug was designed to maximize its effectiveness but reduce fertotoxicity,” explained O'Halloran in the Northwestern statement. “Many cancer drugs cause sterilization; that's why the reproductive tract is really important to focus on in the new stages of drug design. Other body systems get better when people stop taking the drug, but fertility you can't recover.”

The scientists concluded in PLOS One that their in vitro assay allows for rapid evaluation of both established and experimental anticancer drugs on ovarian reserve and can inform the selection of effective and fertility-sparing treatment regimens for women of reproductive age who have cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.